Metastatic Castrate Resistant Prostate Cancer Clinical Trials in Shanghai, Shanghai Municipality
2 recruitingShanghai, Shanghai Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 1Phase 2
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
mCRPC (Metastatic Castration-resistant Prostate Cancer)Metastatic Castrate Resistant Prostate Cancer
Evopoint Biosciences Inc.307 enrolled2 locationsNCT06702995